$ARTH
Arch Therapeutics, Inc.

2014 Q4 Form 10-Q Financial Statement

#000114420415006886 Filed on February 09, 2015

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $870.0K $860.0K $520.0K
YoY Change 67.31% 225.0%
% of Gross Profit
Research & Development $399.7K $530.0K $257.2K
YoY Change 55.4%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $1.270M $1.390M $780.7K
YoY Change 62.69% 44.79% 381.98%
Operating Profit -$1.270M -$780.7K
YoY Change 62.69% 381.98%
Interest Expense $27.77K $2.020M $27.77K
YoY Change 0.0% -35.4%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income $380.0K $640.0K -$810.0K
YoY Change -146.91% -166.67% 305.0%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $379.1K $640.0K -$808.4K
YoY Change -146.9% -166.67% 294.45%
Net Earnings / Revenue
Basic Earnings Per Share $0.01 -$0.01
Diluted Earnings Per Share $0.01 $8.868K -$0.01
COMMON SHARES
Basic Shares Outstanding 73.34M shares 72.08M shares 60.15M shares
Diluted Shares Outstanding 73.42M shares 60.15M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $780.0K $830.0K $950.0K
YoY Change -17.89% 48.21%
Cash & Equivalents $782.7K $833.5K $945.4K
Short-Term Investments
Other Short-Term Assets $40.00K $40.00K $40.00K
YoY Change 0.0% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $820.0K $877.0K $985.0K
YoY Change -16.75% -44.39%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $322.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $10.06K
YoY Change -100.0%
Total Long-Term Assets $4.441K $0.00 $10.38K
YoY Change -57.23% -100.0%
TOTAL ASSETS
Total Short-Term Assets $820.0K $877.0K $985.0K
Total Long-Term Assets $4.441K $0.00 $10.38K
Total Assets $824.4K $877.0K $995.4K
YoY Change -17.18% -44.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $294.2K $175.8K $309.6K
YoY Change -4.97% -44.14%
Accrued Expenses $280.0K $270.0K $200.0K
YoY Change 40.0% 92.86% 1900.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $995.0K $2.724M $512.8K
YoY Change 94.03% 497.81% 5028.01%
LONG-TERM LIABILITIES
Long-Term Debt $960.0K $960.0K $950.0K
YoY Change 1.05% 2.13%
Other Long-Term Liabilities $4.300M $4.090M $30.00K
YoY Change 14233.33%
Total Long-Term Liabilities $5.256M $5.046M $972.5K
YoY Change 440.47% 434.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $995.0K $2.724M $512.8K
Total Long-Term Liabilities $5.256M $5.046M $972.5K
Total Liabilities $6.251M $7.769M $1.485M
YoY Change 320.86% 454.83% 14752.73%
SHAREHOLDERS EQUITY
Retained Earnings -$12.40M -$12.77M
YoY Change 175.8%
Common Stock $76.08K $5.882M $60.15K
YoY Change 26.49% 9680.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.426M -$6.892M -$489.9K
YoY Change
Total Liabilities & Shareholders Equity $824.4K $877.0K $995.4K
YoY Change -17.18% -44.75%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income $379.1K $640.0K -$808.4K
YoY Change -146.9% -166.67% 294.45%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$850.8K -$970.0K -$611.9K
YoY Change 39.04% 46.97% 360.01%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $800.0K 0.000 $1.000M
YoY Change -20.0% -100.0% 700.0%
NET CHANGE
Cash From Operating Activities -$850.8K -970.0K -$611.9K
Cash From Investing Activities 0.000 $0.00
Cash From Financing Activities $800.0K 0.000 $1.000M
Net Change In Cash -$50.85K -970.0K $388.1K
YoY Change -113.1% -1177.78% -4937.68%
FREE CASH FLOW
Cash From Operating Activities -$850.8K -$970.0K -$611.9K
Capital Expenditures $0.00
Free Cash Flow -$611.9K
YoY Change 360.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
782675 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43470 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
876990 USD
CY2014Q3 us-gaap Assets
Assets
876990 USD
CY2014Q4 us-gaap Assets
Assets
824441 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
175832 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
294182 USD
CY2014Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
267835 USD
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
280190 USD
CY2014Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2280000 USD
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
420600 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
537500 shares
CY2014Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9175462 shares
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
5607072 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9175462 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
CY2014Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.17
CY2014Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5255930 USD
CY2014Q3 us-gaap Liabilities
Liabilities
7769433 USD
CY2014Q4 us-gaap Liabilities
Liabilities
6250902 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2723667 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
994972 USD
CY2014Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
955766 USD
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
958530 USD
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
100000 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
125000 USD
CY2014Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3990000 USD
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4172400 USD
CY2014Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5045766 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
72051 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
76076 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5810200 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6893012 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12774694 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12395549 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-6892443 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-5426461 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
876990 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
824441 USD
CY2014Q4 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72076487 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76076487 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72076487 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76076487 shares
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
10391693 USD
CY2014Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2850000 USD
CY2014Q4 arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
7541693 USD
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
2753170 USD
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4593000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8637962 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.36
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.34
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y5M8D
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y6M
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y5M8D
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28750 USD
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
12583 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
28750 USD
CY2013Q4 us-gaap Revenues
Revenues
0 USD
CY2014Q4 us-gaap Revenues
Revenues
0 USD
CY2013Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
523443 USD
CY2014Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
870355 USD
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
257233 USD
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
399735 USD
CY2013Q4 us-gaap Operating Expenses
OperatingExpenses
780676 USD
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
1270090 USD
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-780676 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1270090 USD
CY2013Q4 us-gaap Interest Expense
InterestExpense
27765 USD
CY2014Q4 us-gaap Interest Expense
InterestExpense
27765 USD
CY2013Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-27765 USD
CY2014Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1649235 USD
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-808441 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
379145 USD
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2013Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60145237 shares
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73337085 shares
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
CY2013Q2 arth Percentage Of Outstanding Number Of Shares
PercentageOfOutstandingNumberOfShares
0.04 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.77 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.19 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0025 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024 pure
CY2014Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3707544 shares
CY2013Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
132000 USD
CY2014Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
278000 USD
CY2013Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2000000 USD
CY2013Q2 arth Unit Issued Price Per Share
UnitIssuedPricePerShare
0.50
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.75
CY2013Q2 arth Proceeds From Investors In Contemplation Of Merger
ProceedsFromInvestorsInContemplationOfMerger
2000000 USD
CY2014Q4 us-gaap Notes Payable
NotesPayable
944707 USD
CY2013Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
2764 USD
CY2014Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
2764 USD
CY2014Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
955766 USD
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
958530 USD
CY2013Q4 us-gaap Share Based Compensation
ShareBasedCompensation
131563 USD
CY2014Q4 us-gaap Share Based Compensation
ShareBasedCompensation
278212 USD
CY2013Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
27765 USD
CY2014Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
27764 USD
CY2013Q4 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2014Q4 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
8625 USD
CY2013Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20000 USD
CY2014Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1704 USD
CY2013Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5198 USD
CY2014Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
118350 USD
CY2013Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
62390 USD
CY2014Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12355 USD
CY2013Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-611921 USD
CY2014Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-850845 USD
CY2013Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1000000 USD
CY2014Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2013Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000000 USD
CY2014Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
800000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
388079 USD
CY2014Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-50845 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
557319 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
945398 USD
CY2013Q4 us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q4 us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q4 dei Document Type
DocumentType
10-Q
CY2014Q4 dei Amendment Flag
AmendmentFlag
false
CY2014Q4 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q4 dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
CY2014Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001537561
CY2014Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2014Q4 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2014Q4 dei Trading Symbol
TradingSymbol
ARTH
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76076487 shares
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2013Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60145237 shares
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73422007 shares
CY2013Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2014Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
800000 USD
CY2013Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
CY2014Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2753170 USD
CY2013Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 USD
CY2013Q4 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
CY2014Q4 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
224000 USD
CY2013Q4 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
CY2014Q4 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
1300170 USD
CY2013Q4 arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
0 USD
CY2014Q4 arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
-1300170 USD
CY2014Q4 arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
1300170 USD
CY2014Q4 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
224000 USD

Files In Submission

Name View Source Status
0001144204-15-006886-index-headers.html Edgar Link pending
0001144204-15-006886-index.html Edgar Link pending
0001144204-15-006886.txt Edgar Link pending
0001144204-15-006886-xbrl.zip Edgar Link pending
arth-20141231.xml Edgar Link completed
arth-20141231.xsd Edgar Link pending
arth-20141231_cal.xml Edgar Link unprocessable
arth-20141231_def.xml Edgar Link unprocessable
arth-20141231_lab.xml Edgar Link unprocessable
arth-20141231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v399833_10q.htm Edgar Link pending
v399833_ex31-1.htm Edgar Link pending
v399833_ex31-2.htm Edgar Link pending
v399833_ex32-1.htm Edgar Link pending